These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33852535)

  • 1. Comparison of 18F-labelled fluoro-2-deoxyglucose-PET with conventional computed tomography for staging and response assessment in paediatric and adult patients with nodular lymphocyte-predominant Hodgkin's lymphoma.
    Rauf MS; Khan ZA; Zahir MN; Al-Sweedan S; Al-Kofide A; Alharthy H; Almugbel FA; Osmani A; Elhassan TAM; Khafaga Y; Maghfoor I; Akhtar S
    Nucl Med Commun; 2021 Aug; 42(8):899-906. PubMed ID: 33852535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma.
    Grellier JF; Vercellino L; Leblanc T; Merlet P; Thieblemont C; Weinmann P; Toubert ME; Berenger N; Brière J; Brice P
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2023-30. PubMed ID: 24965842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of
    Panebianco M; Bagni O; Cenfra N; Mecarocci S; Ortu La Barbera E; Filippi L; Codacci-Pisanelli G; Biondi T; Laghi A; Cimino G
    Leuk Res; 2019 Jan; 76():48-52. PubMed ID: 30553980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of
    Marchetti L; Perrucci L; Pellegrino F; Baroni L; Merlo A; Tilli M; Rambaldi I; Maietti E; Carnevale A; Bartolomei M; Giganti M
    J Nucl Med; 2021 Oct; 62(10):1372-1379. PubMed ID: 33712534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including
    Latifoltojar A; Punwani S; Lopes A; Humphries PD; Klusmann M; Menezes LJ; Daw S; Shankar A; Neriman D; Fitzke H; Clifton-Hadley L; Smith P; Taylor SA
    Eur Radiol; 2019 Jan; 29(1):202-212. PubMed ID: 29948084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
    Bangerter M; Moog F; Buchmann I; Kotzerke J; Griesshammer M; Hafner M; Elsner K; Frickhofen N; Reske SN; Bergmann L
    Ann Oncol; 1998 Oct; 9(10):1117-22. PubMed ID: 9834825
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
    Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
    Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil.
    Cerci JJ; Pracchia LF; Soares Junior J; Linardi Cda C; Meneghetti JC; Buccheri V
    Clinics (Sao Paulo); 2009; 64(6):491-8. PubMed ID: 19578651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is ceCT necessary beyond FDG-PET/CT for primary staging in Hodgkin lymphoma?].
    Kajáry K; Molnár Z; Szakáll S; Molnár P; Lengyel Z
    Orv Hetil; 2014 Feb; 155(6):226-30. PubMed ID: 24486846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CT.
    Chiaravalloti A; Danieli R; Caracciolo CR; Travascio L; Cantonetti M; Gallamini A; Guazzaroni M; Orlacchio A; Simonetti G; Schillaci O
    Medicine (Baltimore); 2014 Aug; 93(8):e50. PubMed ID: 25121354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Staging in childhood lymphoma: differences between FDG-PET and CT.
    Hermann S; Wormanns D; Pixberg M; Hunold A; Heindel W; Jürgens H; Schober O; Franzius C
    Nuklearmedizin; 2005 Feb; 44(1):1-7. PubMed ID: 15711722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.
    Gómez León N; Delgado-Bolton RC; Del Campo Del Val L; Cabezas B; Arranz R; García M; Cannata J; González Ortega S; Pérez Sáez MÁ; López-Botet B; Rodríguez-Vigil B; Mateo M; Colletti PM; Rubello D; Carreras JL
    Clin Nucl Med; 2017 Aug; 42(8):595-602. PubMed ID: 28604477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?
    Salaun PY; Gastinne T; Bodet-Milin C; Campion L; Cambefort P; Moreau A; Le Gouill S; Berthou C; Moreau P; Kraeber-Bodéré F
    Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1813-21. PubMed ID: 19499219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
    Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
    J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
    Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M
    Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
    Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
    Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.